The global immunoprotein diagnostic testing market size was valued at USD 10.39 billion in 2025 and is projected to grow from USD 11.07 billion in 2026 to USD 18.38 billion by 2034, registering a CAGR of 6.54% during the forecast period from 2026 to 2034. North America dominated the immunoprotein diagnostic testing market with a market share of 38.5% in 2025.
Immunoprotein Diagnostic Testing (ICI) refers to a specialized diagnostic approach that utilizes immunological methods to detect and analyze specific proteins in the body. These tests play a crucial role in diagnosing various conditions, including infectious and chronic diseases like cancer, by providing personalized results that guide appropriate treatment plans.
The major factors driving the growth of the ICI market include the rising prevalence of infectious and chronic diseases, such as cancer, advancements in screening technologies, a growing geriatric population, and the expansion of healthcare infrastructure. Cancer, being one of the most prevalent chronic diseases, is a major contributor to the market's expansion.
Download a Free Sample To learn more about this report,
Mass Spectrometry Is Expanding Beyond Conventional Protein Testing
The Immunoprotein Diagnostic Testing Market is seeing a shift from conventional electrophoresis and immunofixation toward highly sensitive mass-spectrometry-based protein analysis. This technology can identify monoclonal immunoglobulins by molecular mass, helping laboratories detect low concentrations that can be difficult to distinguish using traditional methods. Automation is also making advanced mass spectrometry more practical for routine clinical laboratories rather than limiting it to specialized research centers. The change is particularly relevant to monoclonal gammopathies, including multiple myeloma and related disorders. As laboratories seek greater analytical sensitivity and clearer interpretation, demand is developing for integrated systems combining immunoglobulin isolation, mass analysis, calibration, automated data processing, and laboratory connectivity.
In November 2025, Thermo Fisher Scientific received U.S. FDA 510(k) clearance for the EXENT Analyser and Immunoglobulin Isotypes GAM Assay for aiding multiple-myeloma diagnosis.
Growing Multiple Myeloma Burden Supports Monoclonal Protein Testing
The continuing burden of multiple myeloma is a major demand driver for immunoprotein diagnostics. Plasma-cell disorders produce abnormal monoclonal proteins, making laboratory measurement of immunoglobulins and free light chains important for disease assessment. Testing can involve serum protein electrophoresis, immunofixation, and serum free-light-chain assays, creating recurring demand across hematology and clinical chemistry laboratories. The International Myeloma Working Group recommends combining serum electrophoresis, immunofixation, and serum free-light-chain testing when screening for monoclonal proteins at diagnosis, except for specific additional requirements in AL amyloidosis. As populations age and more patients live with myeloma, laboratories need reliable protein-testing capacity for diagnosis and ongoing clinical assessment.
In January 2026, the U.S. National Cancer Institute estimated 36,000 new myeloma cases and 10,850 deaths in the United States during 2026.
Technical Variability Can Limit Consistency of Free-Light-Chain Results
Analytical variability remains an important restraint because immunoprotein measurements can be affected by reagent characteristics, antigen concentration, protein structure, and assay methodology. Free-light-chain testing illustrates this problem: international guidance notes that lot-to-lot variation in polyclonal antisera can produce inconsistent results, while very high antigen concentrations can sometimes cause falsely low measurements in nephelometric systems. Polymerization and nonlinear dilution can further complicate interpretation. These limitations require strong quality controls, experienced laboratory staff, repeat testing when appropriate, and careful clinical interpretation. Consequently, laboratories cannot select immunoprotein platforms only on throughput or cost; reproducibility, antigen-excess protection, calibration stability, and validated analytical performance remain important purchasing considerations.
In 2025, the International Myeloma Foundation continued to highlight technical limitations of free-light-chain assays, including lot variation, nonlinear dilution and possible antigen-excess effects.
Near-Patient Inflammatory Protein Testing Can Expand Decentralized Applications
Decentralized measurement of inflammatory proteins provides a different growth opportunity beyond centralized hematology laboratories. C-reactive protein is widely used to evaluate inflammatory conditions, infections, and tissue injury, and compact systems can measure it using small blood samples closer to the patient. Moving suitable protein assays into primary-care and near-patient settings can shorten the interval between sample collection and clinical assessment while expanding testing into locations without large laboratory analyzers. This creates opportunities for compact immunoprotein platforms, single-use cartridges, capillary-blood assays, and simplified digital workflows. Manufacturers that combine laboratory-grade quantitative measurement with easier operation can address clinics and decentralized healthcare facilities in addition to established hospital laboratories.
In January 2025, Malaysia's Medical Device Authority registered Roche's high-sensitivity CRP immunoturbidimetric assay family for laboratory testing, with registration valid through January 2030.
Changing Diagnostic Methods Require Laboratories to Manage Technology Transitions
A key challenge is integrating newer protein-analysis technologies without disrupting established diagnostic workflows. Laboratories have decades of experience with electrophoresis, immunofixation, nephelometry, and immunoturbidimetry, while newer mass-spectrometry systems introduce different analytical principles, software, interpretation methods, quality controls, and staff-training requirements. Results generated by different technologies may not always be directly interchangeable, making method validation and clinical communication important during adoption. Laboratories must also connect new analyzers with middleware and information systems while maintaining turnaround times. This makes technology transition a broader operational issue rather than simply an equipment purchase, particularly for laboratories processing large numbers of monoclonal-protein samples through established testing algorithms.
In June 2026, the American Medical Association adopted an ASCP-backed policy calling for national action on the shortage of medical laboratory professionals, highlighting the workforce pressure facing laboratories adopting increasingly advanced diagnostic technologies.
Kits & Reagents Dominated the Market with 58.9% Share in 2025
The kits & reagents segment accounted for the largest share of the global immunoprotein diagnostic testing market at 58.9% in 2025, driven by their recurring utilization across routine diagnostic procedures and immunoprotein assays. Kits and reagents are essential for detecting and measuring specific proteins associated with diseases, immune responses, and other clinical conditions. Increasing diagnostic testing volumes, expanding laboratory infrastructure, growing prevalence of chronic and infectious diseases, and continuous introduction of advanced assay kits continue to reinforce the segment's dominant market position.
Request Customizationto receive a tailored report.
Chemiluminescence Assay is Projected to Register the Fastest Growth at a CAGR of 7.48%
The chemiluminescence assay segment is projected to register the fastest growth in the immunoprotein diagnostic testing market at a CAGR of 7.48% during the forecast period, supported by increasing demand for sensitive, accurate, and automated diagnostic testing technologies. Chemiluminescence assays enable efficient detection and quantification of biomarkers across numerous clinical applications while supporting high-throughput laboratory workflows. Increasing adoption of automated immunoassay platforms, growing diagnostic testing volumes, and rising demand for rapid and reliable laboratory results continue to strengthen the adoption of chemiluminescence-based testing.
Oncology Dominated the Market with 27.4% Share in 2025
The oncology segment accounted for the largest share of the global immunoprotein diagnostic testing market at 27.4% in 2025, supported by increasing utilization of protein biomarkers for cancer detection, disease monitoring, treatment assessment, and clinical decision-making. Immunoprotein testing helps identify and measure biomarkers associated with different malignancies and supports various stages of cancer management. Growing cancer diagnostic volumes, increasing emphasis on early disease detection, advancements in biomarker-based testing, and expanding adoption of personalized treatment approaches continue to reinforce the oncology segment's leading market position.
Diagnostic Laboratories Dominated the Market with 48.7% Share in 2025
The diagnostic laboratories segment accounted for the largest share of the global immunoprotein diagnostic testing market at 48.7% in 2025, driven by high testing volumes and widespread availability of specialized immunoassay technologies across centralized and independent laboratories. Diagnostic laboratories perform a broad range of immunoprotein tests for oncology, infectious diseases, autoimmune disorders, endocrine conditions, and other clinical applications. Increasing demand for specialized diagnostic services, expansion of laboratory networks, growing adoption of automated testing platforms, and rising requirements for accurate and high-throughput testing continue to support the segment's dominant position.
Speak to an Analystto discuss market opportunities.
North America dominated the immunoprotein diagnostic testing market with the largest 38.5% market share in 2025, representing a market value of USD 4 billion. The region is projected to grow at a CAGR of 6.42% during the forecast period. Its leadership is supported by advanced healthcare infrastructure, extensive diagnostic laboratory networks, increasing prevalence of chronic and immune-related disorders, and widespread adoption of sophisticated diagnostic technologies. Immunoprotein testing is used to measure specific proteins associated with immune responses, inflammation, infections, and various disease conditions. Growing emphasis on early disease detection and personalized treatment is strengthening testing demand. Continued investment in laboratory automation and diagnostic technologies supports North America's position in the global immunoprotein diagnostic testing market.
The United States is an important contributor to the immunoprotein diagnostic testing market due to its sophisticated healthcare infrastructure, extensive clinical laboratory network, strong diagnostic technology industry, and high utilization of advanced laboratory testing. Immunoprotein assays are used across hospitals, diagnostic laboratories, research institutions, and specialty clinics for evaluating immune function, inflammatory conditions, infections, and other disorders. Increasing adoption of automated immunoassay platforms enables laboratories to improve testing throughput, accuracy, and operational efficiency. Growing emphasis on preventive healthcare and earlier disease identification is also supporting diagnostic demand. Continued development of biomarkers, laboratory automation, and precision diagnostics supports growth of the country's immunoprotein diagnostic testing market.
Canada contributes to the immunoprotein diagnostic testing market through its established healthcare system, expanding diagnostic capabilities, and growing demand for laboratory testing associated with chronic, inflammatory, and immune-mediated conditions. Hospitals and clinical laboratories utilize immunoprotein assays to support disease diagnosis, patient monitoring, and treatment decisions. Increasing adoption of automated laboratory equipment is helping healthcare providers improve test processing efficiency and consistency. Growing awareness of early diagnosis and preventive healthcare is further supporting utilization of specialized diagnostic tests. Research institutions also contribute to development and evaluation of emerging biomarkers and testing technologies. Continued modernization of clinical laboratories supports long-term development of Canada's immunoprotein diagnostic testing market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia-Pacific is the fastest-growing region in the immunoprotein diagnostic testing market and is expected to expand at a CAGR of 8.12% during the forecast period. The region accounted for 22.7% of the global market in 2025, representing a market value of USD 2.36 billion. Growth is supported by expanding healthcare infrastructure, increasing diagnostic awareness, large patient populations, and rising prevalence of chronic and immune-related conditions. Development of hospitals and diagnostic laboratories is improving access to specialized immunoprotein testing across major markets. Increasing healthcare expenditure and adoption of automated diagnostic platforms are further supporting market expansion. Growing domestic diagnostic manufacturing capabilities and laboratory modernization support strong development of the immunoprotein diagnostic testing market across Asia-Pacific.
Japan is an important contributor to the immunoprotein diagnostic testing market through its advanced healthcare system, sophisticated diagnostic infrastructure, aging population, and strong medical technology capabilities. Hospitals and laboratories use immunoprotein assays to evaluate inflammatory conditions, immune disorders, infections, and other clinical conditions requiring measurement of specific proteins. Growing requirements for effective management of chronic diseases are supporting demand for accurate and reliable diagnostic technologies. Japan's expertise in laboratory automation, medical devices, and analytical technologies supports development of efficient immunoassay platforms. Increasing integration of laboratory information systems further improves diagnostic workflows. Continued healthcare innovation strengthens Japan's contribution to the Asia-Pacific immunoprotein diagnostic testing market.
China plays a significant role in the immunoprotein diagnostic testing market due to its large patient population, expanding healthcare infrastructure, rapidly developing diagnostic industry, and increasing adoption of advanced laboratory technologies. Hospitals and diagnostic centers are strengthening testing capabilities to support diagnosis and monitoring of inflammatory, infectious, immune-mediated, and chronic diseases. Expansion of laboratory infrastructure beyond major metropolitan areas is improving access to specialized testing services. Domestic diagnostic manufacturers are also developing immunoassay analyzers, reagents, and related laboratory products. Increasing healthcare expenditure and growing emphasis on earlier disease detection are supporting testing volumes. Continued healthcare modernization reinforces China's importance within the Asia-Pacific immunoprotein diagnostic testing market.
Europe accounted for 28.4% of the global immunoprotein diagnostic testing market in 2025, reaching a market value of USD 2.95 billion. The region is anticipated to grow at a CAGR of 6.18% during the forecast period. Market development is supported by established healthcare systems, extensive clinical laboratory infrastructure, growing chronic disease burden, and continued adoption of advanced diagnostic technologies. Immunoprotein testing supports diagnosis and monitoring across multiple clinical areas by providing information regarding immune responses and disease-related biomarkers. Increasing automation of laboratory processes is improving testing efficiency and standardization. Growing emphasis on personalized medicine and early diagnosis is also expanding applications, supporting development of the immunoprotein diagnostic testing market across Europe.
Germany is an important contributor to the immunoprotein diagnostic testing market in Europe due to its advanced healthcare infrastructure, strong diagnostics industry, extensive clinical laboratory network, and established biomedical research capabilities. Hospitals and diagnostic laboratories utilize immunoprotein assays for evaluating immune function, inflammatory diseases, infections, and other medical conditions. Increasing adoption of automated analyzers helps laboratories process larger testing volumes while maintaining consistent performance. Germany's strong life sciences and medical technology ecosystem also supports development of diagnostic instruments, reagents, biomarkers, and laboratory technologies. Growing emphasis on precise diagnosis and efficient disease management further supports adoption. Continued diagnostic innovation strengthens Germany's position within the European immunoprotein diagnostic testing market.
The United Kingdom contributes to the immunoprotein diagnostic testing market through its established healthcare system, strong clinical research ecosystem, diagnostic laboratory capabilities, and increasing emphasis on early disease identification. Immunoprotein tests are utilized across clinical laboratories and hospitals to support diagnosis and monitoring of immune-mediated, inflammatory, infectious, and other conditions. Development of automated testing platforms is improving laboratory efficiency and supporting standardized diagnostic workflows. Research into biomarkers and precision medicine is also broadening potential applications for protein-based diagnostic testing. Increasing integration of diagnostic information into broader patient management processes further supports adoption. Continued clinical research and laboratory modernization support the United Kingdom's contribution to the European immunoprotein diagnostic testing market.
Latin America represented 6.1% of the global immunoprotein diagnostic testing market in 2025, with a market value of USD 0.63 billion. The region is expected to register a CAGR of 6.71% during the forecast period. Growth is supported by improving healthcare infrastructure, expansion of diagnostic laboratory networks, increasing awareness of early disease detection, and rising adoption of automated diagnostic technologies. Growing requirements for diagnosing chronic, inflammatory, infectious, and immune-related diseases are creating demand for specialized immunoprotein assays. Investments in hospital and laboratory modernization are improving access to advanced diagnostic platforms. Increasing availability of diagnostic reagents and analyzers further supports testing capabilities, contributing to continued expansion of the immunoprotein diagnostic testing market across Latin America.
Brazil is an important contributor to the immunoprotein diagnostic testing market in Latin America due to its large healthcare system, substantial patient population, expanding private diagnostic laboratory sector, and increasing adoption of advanced testing technologies. Hospitals and laboratories use immunoprotein assays to support diagnosis and monitoring of inflammatory, infectious, autoimmune, and other health conditions. Growing laboratory automation is improving processing capacity and enabling more efficient handling of diagnostic workloads. Expansion of healthcare services and increasing awareness of preventive testing are also supporting demand. Continued development of clinical laboratories, adoption of advanced analyzers, and investment in healthcare infrastructure reinforce Brazil's importance within the regional immunoprotein diagnostic testing market.
The Middle East and Africa accounted for 4.3% of the global immunoprotein diagnostic testing market in 2025, representing a market value of USD 0.45 billion. The region is projected to expand at a CAGR of 6.29% during the forecast period. Market development is supported by improving healthcare infrastructure, expansion of diagnostic laboratories, increasing chronic disease management requirements, and growing access to advanced testing technologies. Hospitals and laboratories are adopting modern diagnostic systems to improve disease detection and patient monitoring. Development of automated laboratory infrastructure is also increasing the availability and efficiency of specialized testing. Continued investment in hospitals and diagnostic services supports long-term development of the immunoprotein diagnostic testing market across the region.
The UAE contributes to the immunoprotein diagnostic testing market within the Middle East and Africa through its modern healthcare infrastructure, sophisticated diagnostic laboratories, expanding preventive healthcare services, and strong adoption of advanced medical technologies. Hospitals and laboratories utilize immunoprotein assays to support assessment of inflammatory, infectious, immune-related, and other clinical conditions. Increasing adoption of automated diagnostic platforms enables healthcare providers to improve testing efficiency and laboratory workflows. The country's emphasis on advanced healthcare and early disease identification is also supporting demand for specialized laboratory services. Continued investment in diagnostic infrastructure, medical technology, and laboratory automation strengthens the UAE's role in the regional immunoprotein diagnostic testing market.
The immunoprotein diagnostic testing market is slightly fragmented and competitive, with major companies such as Abbott Laboratories, Roche, Thermo Fisher Scientific, Danaher Corporation, Siemens Healthineers, Bio-Rad Laboratories, DiaSorin, bioMérieux, Fujirebio, and QuidelOrtho competing through automated immunoassay systems, protein biomarker testing, and integrated diagnostic platforms. Competition is increasingly driven by high-sensitivity assays, multiplex testing, laboratory automation, point-of-care technologies, and disease-specific biomarkers for autoimmune disorders, cancer, cardiovascular diseases, infections, and neurological conditions. Companies are focusing on expanding assay menus and developing faster and more accessible protein-based diagnostic tests.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com